

Remarks

Upon entry of the foregoing amendment, claims 1-13 are pending in the application, with claim 1, 4, 7, and 8 being the independent claims. Claims 3, 4, 5, 6 and 8 have been amended. Support for these amendments can be found in the specification, *inter alia*, at pages 8-9. New claims 9-13 have been added. Support for these claims can be found in the specification, *inter alia*, at page 5, lines 19-22 and pages 8-9. The specification has also been amended to incorporate the international WO publication number and the language in which the publication was published into the priority information. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Conclusion

It is respectfully believed that this application is now in condition for substantive examination. Early notice to this effect is respectfully requested.

Prompt and favorable consideration of this Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Steffe
Attorney for Applicants
Registration No. 36,688

Date: 8/23/01
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

In the Specification:

The paragraph immediately below the title "Cancer Treatment" at page 1:

The present application is a continuation of the international application, PCT/GB99/02727, filed August 18, 1999, and published in English as WO 00/10590 on March 2, 2000, which claims priority benefit to Great Britain applications GB 9818023.5, filed August 18, 1998 and GB 9820000.9, filed September 14, 1998. The full disclosures of each of these applications is herein incorporated by reference.

In the Claims:

3. (Once amended) A method as claimed in claim 1 [or claim 2 in which] wherein the angiotensin is angiotensin-II.

4. (Once amended) [The use of an angiotensin in the preparation of a medicament for the prevention or treatment of] A pharmaceutical composition to treat or prevent metastasis of cancer cells comprising angiotensin and an excipient or carrier.

5. (Once amended) [A use as claimed in claim 4, in which the medicament is] The pharmaceutical composition of claim 4 adopted for oral, rectal, nasal, topical, vaginal, or parenteral administration.

6. (Once amended) [A use as claimed in claim 5, in which] The pharmaceutical composition of claim 5, wherein the parenteral administration is subcutaneous, intramuscular, intravenous, or intradermal.

8. (Once amended) [The use of an angiotensin in the preparation of a medicament for the induction of] A pharmaceutical composition to induce the expression of B₁ integrin molecules in cancer cells comprising angiotensin and an excipient or carrier.

9. (New) The pharmaceutical composition of claim 8 adopted for oral, rectal, nasal, topical, vaginal, or parenteral administration.

10. (New) The pharmaceutical composition of claim 9, wherein the parenteral administration is subcutaneous, intramuscular, intravenous, or intradermal.

11. (New) The pharmaceutical composition of claim 4 wherein said angiotensin is angiotensin-II.

12. (New) The pharmaceutical composition of claim 8 wherein said angiotensin is angiotensin-II.

13. (New) The method of claim 7, wherein said angiotensin is angiotensin-II.